Oncotelic Therapeutics, Inc. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases
Oncotelic Therapeutics, Inc. (OTLC) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases of $870.27 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-04-15.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPurchases · last filed 2022-04-15
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, purchases for the quarter ending 2020-12-31 was $0.00.
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, purchases for the quarter ending 2020-09-30 was $0.00.
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, purchases for the quarter ending 2020-06-30 was $0.00.
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, purchases for the quarter ending 2020-03-31 was $870.27K.
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, purchases for fiscal 2020 was $870.27K, a 18.86% increase from fiscal 2019.
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, purchases for fiscal 2019 was $732.16K.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases 9 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-15 | $0.00 derived: sum of 2 quarters · filed 2022-04-15 | $0.00 derived: sum of 3 quarters · filed 2022-04-15 | $870.27K 10-K · filed 2022-04-15 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-22 | $0.00 derived: sum of 2 quarters · filed 2021-11-22 | $870.27K 10-Q · filed 2021-11-22 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-20 | $870.27K 10-Q · filed 2021-08-20 | ||
| 2020-03-31 | $870.27K 10-Q · filed 2021-05-24 | |||
| 2019-12-31 | $732.16K 10-K · filed 2021-04-15 |